Stellar Capital Management LLC Has $547,000 Holdings in Edwards Lifesciences Corporation (EW)

Stellar Capital Management LLC maintained its position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,630 shares of the medical research company’s stock at the end of the second quarter. Stellar Capital Management LLC’s holdings in Edwards Lifesciences Corporation were worth $547,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sabal Trust CO lifted its stake in shares of Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after buying an additional 14 shares in the last quarter. Alps Advisors Inc. lifted its stake in shares of Edwards Lifesciences Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after buying an additional 14 shares in the last quarter. Alexandria Capital LLC lifted its stake in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. M Holdings Securities Inc. lifted its stake in shares of Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after buying an additional 62 shares in the last quarter. Finally, Veritable L.P. lifted its stake in shares of Edwards Lifesciences Corporation by 1.2% in the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock worth $738,000 after buying an additional 71 shares in the last quarter. 82.12% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently weighed in on EW. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Cowen and Company reissued an “outperform” rating and issued a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation raised their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded up 0.323% during midday trading on Wednesday, hitting $110.305. 480,024 shares of the company’s stock were exchanged. The firm has a market cap of $23.29 billion, a PE ratio of 33.426 and a beta of 0.62. The stock’s 50-day moving average price is $111.69 and its 200 day moving average price is $111.24. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.76 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 182,201 shares of company stock worth $20,768,154. Insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Stellar Capital Management LLC Has $547,000 Holdings in Edwards Lifesciences Corporation (EW)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/10/11/stellar-capital-management-llc-has-547000-holdings-in-edwards-lifesciences-corporation-ew.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply